Research
Hormonal
Glucagon-like peptide 1 receptor agonists consistently reduce three-point major adverse cardiovascular events (MACE) in patients with overweight, obesity, and established cardiovascular disease (CVD) with and without diabetes.
Practitioners can consider glucagon-like peptide 1 receptor agonists as effective treatments for reducing cardiovascular events in eligible patients.
StrongSupportsmedium confidence
Across large CV outcome trials, glucagon-like peptide 1 receptor agonists consistently reduce three-point major adverse CV events (MACE) in patients with overweight, obesity and established CVD with and without diabetes.
Why this rating
Based on large cardiovascular outcome trials mentioned in the abstract.
Source
Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery
Itxaso K Villelabeitia et al. · Heart · 2026
DOI 10.1136/heartjnl-2025-326812
Meta-analysisCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide and tirzepatide improve symptoms and functional capacity in obesity-related heart failure of preserved ejection fraction and reduce worsening heart failure events.Strong
- Metabolic bariatric surgery is associated with durable weight loss and lower observed rates of major adverse cardiovascular events (MACE), heart failure, and all-cause mortality compared with non-surgical care.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →